Syndecan-1 expression in locally invasive and metastatic prostate cancer.

OBJECTIVES To determine the significance of syndecan-1 expression, a cell-surface heparan sulfate proteoglycan in localized and metastatic prostate cancer. METHODS We performed a retrospective analysis of 76 men with Gleason sum 6 or 7 prostate cancer treated by radical prostatectomy and a separate cohort of 75 men with metastatic prostate cancer. Syndecan-1 immunoreactivity was measured in primary prostate specimens or in samples from metastatic sites and correlated with patient outcome. RESULTS Syndecan-1 was expressed in normal basal and secretory epithelial cells, 26% of radical prostatectomy specimens, and 35% of metastatic disease. No association was found between syndecan-1 positivity and prostate-specific antigen recurrence in the collective cohort of Gleason sum 6 and 7 cancers. However, when stratified by Gleason sum, syndecan-1 immunoreactivity (immunoreactivity score 150 or greater) was associated with a greater recurrence rate in Gleason sum 7 cancers. Expression of syndecan-1 was significantly greater in soft tissue than in bone metastasis (P = 0.048, Fisher's exact test). CONCLUSIONS Consistent with a possible biochemical role for syndecan-1 in prostate cancer progression and metastasis, syndecan-1 expression correlated with serologic recurrence in Gleason sum 7 prostate cancer and was highly expressed in soft-tissue metastases.

[1]  L. Bubendorf,et al.  Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.

[2]  P. Heikkilä,et al.  High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. , 2001, Lung cancer.

[3]  M. V. van Oers,et al.  Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. , 2002, Blood.

[4]  H. Friess,et al.  Syndecan‐1 expression is up‐regulated in pancreatic but not in other gastrointestinal cancers , 2000, International journal of cancer.

[5]  X. Wu,et al.  A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1. , 2001, Cancer research.

[6]  M. Bernfield,et al.  Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice , 2000, Nature Genetics.

[7]  Alan C. Rapraeger,et al.  Syndecan-Regulated Receptor Signaling , 2000, The Journal of cell biology.

[8]  J. Epstein,et al.  E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. , 1999, Urology.

[9]  K. Nackaerts,et al.  Heparan sulfate proteoglycan expression in human lung‐cancer cells , 1997, International journal of cancer.

[10]  S. Nordling,et al.  A prognostic value of syndecan-1 in gastric cancer. , 2000, Anticancer research.

[11]  P. Heikkilä,et al.  Syndecan-1 expression has prognostic significance in head and neck carcinoma , 1999, British Journal of Cancer.

[12]  A. Rapraeger,et al.  Syndecan-1 signals independently of beta1 integrins during Raji cell spreading. , 2000, Experimental cell research.

[13]  K. Kikuchi,et al.  Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. , 2001, Lung cancer.

[14]  M. Jalkanen,et al.  Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Grénman,et al.  Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. , 1999, Gynecologic oncology.

[16]  A. Semjonow,et al.  Radical prostatectomy: survival outcome and correlation to prostate-specific antigen levels. , 2000, Anticancer research.

[17]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[18]  S. Grénman,et al.  Immunohistochemical localization of syndecan‐1 in normal and pathological human uterine cervix , 1994, The Journal of pathology.

[19]  J. Woodliff,et al.  Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen , 1993 .

[20]  H. Joensuu,et al.  Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. , 1994, British Journal of Cancer.

[21]  Douglas S Scherr,et al.  High expression of the Met receptor in prostate cancer metastasis to bone. , 2002, Urology.

[22]  Dianjun Cao,et al.  High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity , 2000 .

[23]  A. Woods,et al.  Syndecans: synergistic activators of cell adhesion. , 1998, Trends in cell biology.

[24]  Y. Kohgo,et al.  Reduced expression of syndecan‐1 in human hepatocellular carcinoma with high metastatic potential , 1997 .

[25]  Y. Suehiro,et al.  Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. , 2002, International journal of oncology.

[26]  L. Sapinoso,et al.  Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer , 2001, Nature Genetics.